Management of Impaired Renal Function and Hyperkalemia

Patient Assessment

• The American Journal of Kidney Diseases and Circulation recommend that patients with Stage 3B chronic kidney disease (eGFR 39 mL/min/1.73m²) and hyperkalemia (5.4 mEq/L) be assessed for elevated creatinine and glucose levels, which can increase the risk of heart failure and kidney disease progression 1, 2
• Elevated glucose levels, suggesting possible diabetes or prediabetes, can increase the risk of heart failure and kidney disease progression, according to Circulation 2

Management Strategy

• The American Heart Association, as reported in Circulation, suggests avoiding medications that can worsen hyperkalemia, including NSAIDs and potassium supplements, in patients with hyperkalemia 3, 4
• The American College of Cardiology, as reported in Circulation, recommends counseling patients to limit dietary potassium intake to manage hyperkalemia 5
• The British Journal of Pharmacology and Circulation recommend monitoring potassium levels closely, initially within 1 week and then regularly based on clinical stability, to manage hyperkalemia 6, 4
• The American Journal of Kidney Diseases and Circulation suggest adding an SGLT2 inhibitor to reduce hyperkalemia risk (HR 0.84; 95% CI, 0.76-0.93) while providing cardiovascular and renal protection in patients with impaired renal function and hyperkalemia 1, 2
• The Kidney International recommends considering loop diuretics if volume overload is present to help manage hyperkalemia 7

Monitoring Plan

• The British Journal of Pharmacology and Circulation recommend checking potassium and renal function within 1 week of any medication changes to monitor hyperkalemia 6, 4
• The Circulation recommends monitoring potassium levels monthly for the first 3 months after stabilization, then every 3 months if stable, to manage hyperkalemia 8, 4
• The Circulation suggests assessing volume status regularly to guide diuretic therapy in patients with hyperkalemia 9
• The Circulation recommends monitoring glucose control, especially if SGLT2 inhibitor is initiated, to manage hyperkalemia and diabetes 2

Cautions and Pitfalls

• The Circulation warns against triple RAAS inhibition (ACE inhibitor + ARB + MRA) due to extremely high hyperkalemia risk in patients with impaired renal function and hyperkalemia 2